Compare ACGL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACGL | ONC |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | Bermuda | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 34.8B |
| IPO Year | 1995 | N/A |
| Metric | ACGL | ONC |
|---|---|---|
| Price | $100.30 | $347.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $107.87 | ★ $370.25 |
| AVG Volume (30 Days) | ★ 2.4M | 241.8K |
| Earning Date | 02-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.66 | N/A |
| EPS | ★ 11.60 | 0.58 |
| Revenue | ★ $19,929,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | N/A | $895.40 |
| Revenue Next Year | $4.56 | $22.04 |
| P/E Ratio | ★ $8.50 | $600.76 |
| Revenue Growth | 14.27 | ★ 50.43 |
| 52 Week Low | $82.45 | $196.45 |
| 52 Week High | $103.39 | $385.22 |
| Indicator | ACGL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 53.80 |
| Support Level | $94.84 | $340.00 |
| Resistance Level | $102.90 | $358.38 |
| Average True Range (ATR) | 2.40 | 9.75 |
| MACD | 0.39 | -0.25 |
| Stochastic Oscillator | 73.83 | 60.47 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.